References
- Batist G, Ramakrishnan G, et al. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454.
- Benjamin RS, Riggs CE, Jr, et al. (1977). Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416–1420.
- Bonadonna G, Monfardini S, et al. (1970). Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30:2572–2582.
- Casas JGG, Sánchez-Baeza F, et al. (1992). Inhibition of rat liver microsomal lipid peroxidation elicited by simple 2,2-dimethylchromenes and chromans structurally related to precocenes. J Agric Food Chem 40:585–590.
- Cowens JW, Creaven PJ, et al. (1993). Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 53:2796–2802.
- Drummond DC, Meyer O, et al. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumours. Pharmacol Rev 51:691–743.
- Ewer MS, Martin FJ, et al. (2004). Cardiac safety of liposomal anthracyclines. Semin Oncol 31:161–181.
- Gabizon A, Catane R, et al. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992.
- Harris L, Batist G, et al. (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25–36.
- Israel VP, Garcia AA, et al. (2000). Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 78:143–147.
- Irurre J, Jr, Casas, J, et al. (1993). Inhibition of rat liver microsomal lipid peroxidation elicited by 2,2-dimethylchromenes and chromans containing fluorinated moieties resistant to cytochrome P-450 metabolism. Bioorg Med Chem 1:219–225.
- Judson I, Radford JA, et al. (2001). Randomised, phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870–877.
- Lasic DD. (1998). Novel applications of liposomes. Trends Biotechnol 16:307–321.
- Lipinski CLF, Dominy B, et al. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and developement settings. Adv Drug Deliv Rev 23:3–25.
- Lipotec Iro. Toxicity studies on healthy male B6D2F1 mice after i.p. administration of LIP 136 and DXR in liposomes without the antioxidant.
- Messequer A. (2006). Lipochromane: An improved Chemopreventative Agent. Date on file. Expert Report.
- Mross K, Maessen P, et al. (1988). Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517–526.
- Rahman A, Treat J, et al. (1990). A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093–1100.
- Robert J, Illiadis A, et al. (1982). Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18:739–745.
- Sanvicens NG-VV, Masip I, et al. (2004). Sodium nitroprusside (SNP) induces apoptosis in 661W photoreceptor cells in which calpains and caspases are involved and can be inhibited by the ROS scavenger 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl- 1(2H)-benzopyran (CR-6). J Biol Chem 279:39268–39278.
- Shapiro CL, Ervin T, et al. (1999). Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol 17:1435–1441.
- Singal PK, Iliskovic N. (1998). Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905.
- Valero V, Buzdar AU, et al. (1999). Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17:1425–1434.